|
Heart
|   |
|
Heart
| |
Heart – (SCARD)
- Protocol applies to primary malignant cardiac tumors. Hematolymphoid neoplasms are not included.
Specimen and Surgical Procedure
Specimen .............................................................................
- Atrium
- Ventricle
- Interventricular septum
- Other (specify)
Procedure ............................................................................
- Resection
- Excisional biopsy
- Other (specify)
Specimen integrity ................................................................
- Intact
- Disrupted
- Indeterminate
Specimen laterality ..............................................................
- Right
- Left
- Other (specify)
Tumor
Tumor site(s) (select all that apply) ...........................................
- Pericardium
- Right ventricle
- Left ventricle
- Right atrium
- Left atrium
- Interventricular septum
- Other (specify)
Tumor size* (greatest dimension) ............................................. __ cm
Histologic type** ....................................................................
Histologic grade*** ................................................................
- Grade 1
- Grade 2
- Grade 3
- Not applicable
- Cannot be determined
- Other (specify)
Tumor extension (select all that apply) ......................................
- No involvement of adjacent tissue(s)
- Involvement of adjacent tissue(s)
- Other organ involvement (specify)
- Cannot be determined
Margins .................................................................................
- Negative for tumor
- Involved by tumor (specify site(s) if known)
- Not applicable
- Cannot be assessed
Treatment effect ....................................................................
- Not identified
- Present (specify: ___% residual viable tumor)
- Not applicable
- Cannot be determined
Lymph-vascular invasion.........................................................
- Present
- Not identified
- Indeterminate
* The greatest diameter of the tumor in centimeters should be recorded.
There is no published staging system for primary cardiac tumors.
** For consistency in reporting, the histologic classification published by the
World Health Organization (WHO) for tumors of the heart is recommended.
*** Pathologists should grade the tumor and indicate the grading system used.
Most malignant tumors of the heart are sarcomas. Necrosis of groups of
cells and mitotic rates of greater than 5 mitoses per 10 high-power fields
have been associated with reduced survival. Parameters of the grading system
for sarcomas of the Federation Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) are shown below.
Tumor Differentiation
Score 1: Sarcomas closely resembling normal adult mesenchymal tissue
(eg, low-grade leiomyosarcoma)
Score 2: Sarcomas for which histologic typing is certain (eg, myxoid fibrosarcoma)
Score 3: Undifferentiated, angiosarcoma
Mitotic Count
Score 1: 0-9 mitoses per 10 HPF*
Score 2: 10-19 mitoses per 10 HPF
Score 3: ≥20 mitoses per 10 HPF
Tumor Necrosis
Score 0: No necrosis
Score 1: <50% tumor necrosis
Score 2: ≥50% tumor necrosis
Histologic Grade
Grade 1: Total score 2, 3
Grade 2: Total score 4, 5
Grade 3: Total score 6, 7, 8
* A high-power field (HPF) measure 0.1734 mm2
CAP Version 3.0.0.0